ANTISENSE OLIGONUCLEOTIDES MARKET ANALYSIS

Regional Analysis

Antisense Oligonucleotides Market Regional Analysis:-

North America is expected to be the dominant region in the global antisense oligonucleotides market over the forecast period. This is owing to increasing approvals of new antisense oligonucleotide drugs in the region. For instance, in 2018, U.S. FDA approved Nusinersen, which is marketed as Spinraza from Biogen Inc.—a multinational biotechnology company. Nusinersen is the first drug approved for the treatment of Spinal muscular Atrophy (SMA). Moreover, robust pipeline is expected to contribute significantly to North America antisense oligonucleotides market growth. For instance, in 2017, Bio Path Holding’s—an oncology focused biotechnology company— drug BP 1001 (liposomal Grb2 antisense oligonucleotide) was in phase 2 clinical trials. BP 1001 (liposomal Grb2 antisense oligonucleotide) is used to treat chronic myelogenous leukemia.

Key players in Europe are focusing on strategic mergers and acquisitions in order to enhance their product offerings in antisense oligonucleotides. This is further expected to aid in growth of the Europe antisense oligonucleotides market size. For instance, in 2014, Astra Zeneca Plc.,—a multinational pharmaceutical and biopharmaceutical company—merged with Ionis Pharmaceuticals, a pharmaceutical company. Astra Zeneca Plc. has strategically merged with Ionis Pharmaceuticals to develop delivery methods for antisense oligonucleotides, which would help in targeting the desired tissue more effectively. The other objective of this merger was to develop Ligand Conjugation Antisense (LICA) Technology. Furthermore, robust pipeline of key players is also expected to aid in growth of the market to a certain extent. For instance, in 2016, Ionis Pharmaceuticals, a pharmaceutical company completed phase 2 clinical trial of its drug IONIS STAT 3Rx. IONIS STAT 3Rx is used in treatment of advanced cancers and lymphoma.